QRxPharma may face more trials for MoxDuo
04 July, 2012 by Dylan Bushell-EmblingQRxPharma will meet with the FDA in August to discuss whether more trials of MoxDuo IR are required or existing data reanalysed, but CEO John Holaday is confident its application is “more than adequate for approval”.
AHG, CSIRO team for stem cell research
03 July, 2012 by Dylan Bushell-EmblingAllied Healthcare Group (ASX:AHZ) and the CSIRO have joined forces to develop tissue engineering technologies with the potential to aid tissue repair in the heart.
Registrations now open for the R&D Tax Incentive
03 July, 2012 by AusBiotechThe new financial year has heralded the launch of the application form for the registration of R&D activities under the new R&D Tax Incentive, which opened on 1 July 2012.
CBio to merge with Inverseon
02 July, 2012 by Dylan Bushell-EmblingBrisbane's CBio (ASX:CBZ) plans to merge with US-based Inveseon to create new inflammatory disease focused biotech, Invion.
pSivida enrols first patient for uveitis trial
02 July, 2012 by Dylan Bushell-EmblingpSivida (ASX:PVA) has signed up the first patient for an investigator-sponsored trial of its inserts and ILUVIEN drug in eye disease posterior uveitis.
Phosphagenics enters horse supplement tie-up
02 July, 2012 by Dylan Bushell-EmblingPhosphagenics (ASX:POH) and Equine Nutrition Australia will collaborate to create equine nutritional supplements using the former's TPM technology.
Bioxyne's COPD clinical trial disappoints
29 June, 2012 by Dylan Bushell-EmblingShares in Bioxyne (ASX:BSN) sank 82% on Thursday, after the company revealed a trial of HI 164 OV showed clinical benefit only in COPD patients younger than 65.
Victorian Government opens ‘Investing in Manufacturing Technology’ Grants
28 June, 2012 by AusBiotechGrants of up to $250,000 are available under the Investing in Manufacturing Technology (IMT) grants scheme to assist businesses to purchase and integrate new technologies into their business.
Stable antibody breakthrough solves sticky biotech problem
28 June, 2012 by Tim DeanResearchers at the Garvan Institute have developed a new technique to produce antibodies that are resistant to clinging together into a sticky mess, solving a longstanding technical problem in biotech.
Bell Potter downgrades QRxPharma after FDA shock
28 June, 2012 by Tim DeanBell Potter Securities has reset its optimistic target valuation of QRxPharma from $3.69 to $1.26 after the FDA failed to approve the company’s MoxDuo IR.
BioDiem licenses hepatitis vaccine tech from UC
27 June, 2012 by Dylan Bushell-EmblingBioDiem (ASX:BDM) has signed its second vaccine technology licensing deal this week, securing exclusive rights to IP with potential applications in hepatitis B and D.
QRxPharma shares tumble after FDA knockback for MoxDuo IR
27 June, 2012 by Tim DeanShares down over 50% after the FDA requests more information on safety and efficacy from QRxPharma on its MoxDuo IR before granting regulatory approval.
Final days for early bird for AusBiotech 2012
26 June, 2012 by AusBiotechRegister in the next four days (by 30 June) for the industry event of the year and save $250 with early bird rates.
Feature: Raising the bar on IP
26 June, 2012 by Tim DeanFrom 15 April 2013 patents will be significantly harder to secure in Australia. We look at the implications of the Raising the Bar bill on Australian life science organisations.
BioDiem closes dengue fever deal
25 June, 2012 by Dylan Bushell-EmblingBioDiem (ASX:BDM) and ANU have finalised the terms of the exclusive licensing deal covering a vaccine technology for diseases such as dengue fever.
